



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

MM11253

Cat. No.:	HY-108530		
CAS No.:	345952-44-5		
Molecular Formula:	C ₂₈ H ₃₀ O ₂ S ₂		
Molecular Weight:	462.67		
Target:	RAR/RXR		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (270.17 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.1614 mL	10.8068 mL	21.6137 mL
	5 mM		0.4323 mL	2.1614 mL	4.3227 mL
	10 mM		0.2161 mL	1.0807 mL	2.1614 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

MM11253 is a potent and selective RAR γ antagonist with an IC₅₀ of 44 nM. MM11253 has lower inhibition of RAR α , RAR β and RXR α . MM11253 blocks the growth inhibitory effects of RAR γ -selective agonists^{[1][3]}.

IC₅₀ & Target

RAR γ 44 nM (IC ₅₀)	RAR γ 44 nM (IC ₅₀)	RAR γ 44 nM (IC ₅₀)	RAR α 1000 nM (IC ₅₀)
RAR α 1000 nM (IC ₅₀)	RAR α 1000 nM (IC ₅₀)	RAR β >1000 nM (IC ₅₀)	RAR β >1000 nM (IC ₅₀)
RAR β >1000 nM (IC ₅₀)	RXR α >1000 nM (IC ₅₀)		

In Vitro

MM11253 blocks the ability of MM11254 and MM11389 to inhibit squamous cell carcinoma cell growth^[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. M I Dawson, et al. Retinoic acid (RA) receptor transcriptional activation correlates with inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase (ODC) activity by retinoids: a potential role for trans-RA-induced ZBP-89 in ODC inhibition. *Int J Cancer*. 2001 Jan 1;91(1):8-21.
- [2]. Q Le, et al. Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids. *Oncogene*. 2000 Mar 9;19(11):1457-65.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA